吴 婷

吴婷,教授,博士生导师, 1994年毕业于上海医科大学药学院;2000年毕业于复旦大学药学院(原上海医科大学药学院),获博士学位。2003年1月起进入厦门大学。主要研究方向为疫苗临床试验和传染病的流行病学研究,目前做为国家传染病诊断试剂与疫苗工程技术研究中心“临床试验与流行病学研究”方向的组长开展传染病防控及流行病学相关研究,包括人乳头瘤病毒(HPV)系列疫苗的I-III期临床研究及相关流行病学研究;戊型肝炎病毒相关流行病学研究;巨细胞病毒母婴传播风险研究;带状疱疹病毒疫苗临床研究。作为项目负责人之一完成HPV 16/18型双价疫苗的临床研究并提交注册申请,该疫苗有望成为首个上市的国产宫颈癌疫苗,相关文章已在J Natl Cancer Inst.杂志发表。曾作为主要研究人员之一完成国家一类新药重组戊型肝炎病毒疫苗III期临床试验,该疫苗现已获得新药证书和生产文号,成为世界上第一个成功上市的戊肝疫苗。作为主要研究人员主持或参与多项国家传染病重大科技专项、国家自然科学基金项目、福建省科技重大专项等多个项目。


主要学术兼职:

2016.9-今:《病毒学报》编委

2016.9-今:中华预防医学会疫苗与免疫分会,第一届委员会委员2015.5-今:中国优生科学协会阴道镜和宫颈病理学分会(CSCCP),第一届委员会委员

2011-今:欧盟第7框架“疾病控制工具”(DISCONTOOLS - EU FP7)项目,食物源性戊型肝炎病毒专家组成员


从事或正在承担的研究项目及所负责任:

国家自然科学基金,81673240“大龄妇女高危型人乳头瘤病毒感染特征及影响因素的前瞻性研究”,2017.1-2020.12,项目负责人,65万;

国家科技重大专项,2018ZX09303005-002,“戊型肝炎疫苗的质量控制研究、疫苗标准品研究”,2018.1-2020.12,子课题负责人,215.14万;

重大新药创制项目,2012ZX09101316,“重组人乳头瘤病毒16/18 型双价疫苗临床研究”,2012.1-2015.12,其中“临床研究”部分的负责人,已结题;

863项目诊断试剂关键性原辅材料的研制(课题编号:2011AA02A114),2011-2015,项目负责人,已结题;

艾滋病和病毒性肝炎等重大传染病防治项目“乙型病毒性肝炎免疫预防新策略研究”(2012.1-2015.12,课题编号: 2012ZX10002001):为子课题五中任务“HBsAg阳性人群的长期转归研究”(任务编号:2012ZX10002001-005-003)的任务负责人;

重大新药创制“重组戊型肝炎疫苗IV期临床试验(课题编号:2013ZX09101017)” ,2012.1-2015.12,参加,已结题;

863重大项目(2007-2010):“重组戊型肝炎疫苗三期临床研究”(2006AA02A209),参加,已结题。该课题完成了戊肝疫苗的III期临床研究,结果发表于《Lancet》。课题执行团队被评为“十一五规划国家科技计划优秀执行团队”, 本项目参展“十一五”国家重大科技成果展。


发明专利:

l   吴婷,伍小路,罗文新,张军,夏宁邵. 用于免疫或制备单克隆抗体的方法和组合物. 中国发明专利申请号:200610081554.4,授权日:2012.6

近五年发表论文(第一和/或通讯作者):

[1] Qiao YL*, Wu T*, Li RC*, Hu YM*, Wei LH*, Li CG*, Chen W*, Huang SJ, Zhao FH, Li MQ, Pan QJ, Zhang X, Li Q, Hong Y, Zhao C, Zhang WH, Li YP, Chu K, Li M, Jiang YF, Li J, Zhao H, Lin ZJ, Cui XL, Liu WY, Li CH, Guo DP, Ke LD, Wu X, Tang J, Gao GQ, Li BY, Zhao B, Zheng FX, Dai CH, Guo M, Zhao J, Su YY, Wang JZ, Zhu FC, Li SW, Pan HR, Li YM, Zhang J, Xia NS. Efficacy, safety and immunogenicity of a Escherichia coli-produced bivalent human papillomavirus vaccine in adult women——A Randomized Clinical Trial. J Natl Cancer Inst. 2019 (共同第一作者) (IF: 11.238)

[2] Su YY, Wei FX, Huang XM, Li YF, Qiu LX, Hu FF, Yang CQ, Zhang YJ, Yin K, Li MQ, Wu T*, Xia NS, Zhang J*. Prevalence, concordance and transmission of human papillomavirus infection among heterosexual couples in Liuzhou, China: an observational perspective study. J Infect Dis, 2019, Accepted (共通讯作者) (IF: 5.186)

[3] Wei FX, Guo M, Huang SJ, Li MQ, Cui XL, Su YY, Wu X, Ma XJ, Zheng Y, Huang Y, Wang L, Pan LL, Wu T*, Zhang J*, Xia NS. Sex differences in the incidence and clearance of anogenital human papillomavirus infection in Liuzhou, China: an observational cohort study. Clin Infect Dis, 2019, accepted (共通讯作者) (IF: 9.117)

[4] Wei FX, Li MQ, Wu X, Yin K, Lan J, Sheng W, Guo M, Huang SJ, Wang Y, Li YP, Li RC, Su YY, Wu T*, Zhang J, and Xia NS. The Prevalence and Concordance of Human Papillomavirus Infection in Different Anogenital Sites among Men and Women in Liuzhou, China: a Population-Based Study. Int J Cancer, 2018, 142(6):1244-1251 (IF: 7.360)

[5] Wei FX, Sheng W, Wu X, Yin K, Lan J, Huang Y, Ma XJ, Zheng Y, Zhuang SJ, Huang SJ, Su YY, Li MQ*, Wu T*, Zhang J, and Xia NS. Incidence of genital warts in Liuzhou, south China: a comparison of data from a prospective study and from the national surveillance system. Emerging Microbes & Infections, 2017, 6, e113 (共通讯作者) (IF: 6.032)

[6] Su YY, Huang SJ, Guo M, Zhao J, Yu H, He WG, Jiang HM, Wang YJ, Zhang XF, Cai JP, Yang CL, Wang ZZ, Zhu FC, Wu T*, Zhang J*, Xia NS. Persistence of antibodies acquired by natural hepatitis E virus infection and the effects of booster vaccination. Clin Microbiol Infect, 2017, 23(5): 336.e1-336.e4  (共通讯作者) (IF: 5.3)

[7] Wei FX, Yin K, Wu X, Lan J, Huang SJ, Sheng W, Zhao J, Su YY, Wang Y, Li YP, Li RC, Zhang J, Li MQ*, Wu T*, and Xia NS. Human papillomavirus (HPV) prevalence and associated factors in women and men in south China: a population-based study. Emerging Microbes & Infections, 2016, 5(11): e119  (共通讯作者) (IF:6.032)

[8] Chen S, Zhou Z, Wei FX, Huang SJ, Tan Z, Fang Y, Zhu FC, Wu T*, Zhang J*, Xia NS. Modeling the long-term antibody response of a hepatitis E vaccine. Vaccine, 2015, 33: 4124-4129. (共通讯作者) (IF:3.624)

[9] Wu T#, Hu YM#*, Li J#, Chu K, Huang SJ, Zhao H, Wang ZZ, Yang CL, Jiang HM, Wang YJ, Lin ZJ, Pan HR, Sheng W, Wei FX, Li SW, Wang Y, Zhu FC, Li CG, Zhang J*, Xia NS. Immunogenicity and safety of an E. coli–produced bivalent human papillomavirus (type 16 and 18) vaccine: a randomized controlled phase 2 clinical trial. Vaccine, 2015, 33: 3940–3946. (共第一作者) (IF:3.624)

[10] Li SW, Zhao QJ, Chen S, Wu T*, Zhang J, Xia NS. The development of a recombinant hepatitis E vaccine HEV 239. Human Vaccines & Immunotherapeutics, 2015, 11(4): 908--914.(综述,通讯作者,IF: 2.366)

[11] Wu T, Zhang J, Xia NS*. Rationally respond to post-vaccination adverse events. Sci China Life Sc, 2014, 57 (5): 557–560. (综述,IF:2.02)

[12] Zhao H, Lin ZJ, Huang SJ, Li J, Liu XH, Guo M, Zhang J, Xia NS, Pan HR*, Wu T*, Li CG*. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. Human Vaccines & Immunotherapeutics, 2014, 10 (3):740-6(IF: 2.366, 共通讯作者)

非第一且非通讯作者论文:

[13] Lin C, Slama J, Gonzalez P, Goodman MT, Xia N, Kreimer AR, Wu T, …, Clifford GM. Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infect Dis. 2019 Jun 13

[14] Kmush BL, Yu H, Huang S, Zhang X, Wu T, Nelson KE, Labrique AB. Long-term antibody persistence after hepatitis E virus infection and vaccination in Dongtai, China. Open Forum Infect Dis. 2019, 28;6(4):

[15] Hu YM*, Guo M*, Li CG*, Chu K, He WG, Zhang J, Gu JX, Li J, Zhao H, Wu XH, Lin BZ, Lin ZJ, Yao XM, Li YF, Wei FX, Huang Y, Su YY, Zhu FC, Huang SJ, Pan HR, Wu T, Zhang J#, Xia NS#. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV vaccine in girls vs 3 doses in young women. Sci China Life Sci. 2019

[16] Wei FX, Su YY, Yao XM, Cui XL, Bian LH, Yin K, Yu XJ, Zhuang CL, Bi ZF, Huang SJ, Li MQ, Wu T, Xia NS, Zhang J. Sex differences in the incidence and clearance of anal human papillomavirus infection among heterosexual men and women in Liuzhou, China: an observational cohort study. Int J Cancer, 2019, Accepted

[17] Chen Z, Lin S, Duan J, Luo Y, Wang S, Gan Z, Yi H, Wu T, Huang S, Zhang Q, Lv H. Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial. Clin Microbiol Infect. 2019

[18] Wang K, Zhou L, Zhang X, Song C, Chen T, Li J, Zheng M, Wang Y, Zheng Q, Zheng Z, Yu H, Wu T, Gu Y, Zhang J, Zhao Q, Li S, Xia N. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A. Antiviral Res. 2019

[19] Huang Y, Guo X, Song Q, Wang H, Yu H, Zhang Y, Qiao E, Xue W, Li X, Zhuang S, Wei F, Li T, Ge S, Wu T, Xia N, Zhang J. Cytomegalovirus Shedding in Healthy Seropositive Female College Students: A 6-Month Longitudinal Study. J Infect Dis. 2018, 217(7): 1069-1073.

[20] Van der Poel WHM#*, Dalton HR, Johne R, Pavio N, Bouwknegt M, Wu T, Cook N, Meng XJ. Knowledge gaps and research priorities in the prevention and control of hepatitis E virus infection. Transbound Emerg Dis., 2018, 65 Suppl 1:22-29.

[21] Gu Y, Wei M, Wang D, Li Z, Xie M, Pan H, Wu T, Zhang J, Li S, Xia N. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Vaccine., 2017, 35: 4637-4645

[22] Wen GP, Tang ZM, Wang SL, Ji WF, Cai W, Zhang X, Huang SJ, Wu T, Zhang J, Zheng ZZ*, Xia NS*. Classification of human and zoonotic group hepatitis E virus (HEV) using antigen detection. Appl Microbiol Biotechnol, 2017, 101(23-24): 8585-8594

[23] Wang X, Li M, Li S, Wu T, Zhang J, Xia N*, Zhao Q*. Prophylaxis against hepatitis E: at risk populations and human vaccines. Expert Rev Vaccines. 2016, 5: 1-13.(综述,IF 4.210)

[24] Zhang J*, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, Wang H, Jiang HM, Wang YJ, Yan Q, Guo M, Liu XH, Li JX, Yang CL, Tang Q, Jiang RJ, Pan HR, Li YM, Shih JW, Ng MH, Zhu FC*, Xia NS*. Long-Term Efficacy of a Hepatitis E Vaccine. New Engl J Med, 2015, 372(10): 914-922. (IF 54.42)

[25] Wen GP, Tang ZM, Yang F, Zhang K, Ji WF, Cai W, Huang SJ, Wu T, Zhang J, Zheng ZZ*, Xia NS*. A valuable antigen detection method for diagnosis of acute hepatitis e. J Clin Microbiol. 2015, 53(3): 782-8. (IF)

[26] Zhu FC, Huang SJ, Wu T, Zhang XF, Wang ZZ, Ai X, Yan Q, Yang CL, Cai JP, Jiang HM, Wang YJ, Ng MH, Zhang J*, Xia NS. Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in China. PLoS ONE, 2014, 9(1): e87154. doi: 10.1371/journal.pone.0087154(IF:4.411)

[27] Hu YM, Huang SJ, Chu K, Wu T, Wang ZZ, Yang CL, Cai JP, Jiang HM, Wang YJ, Guo M, Liu XH, Huang HJ, Zhu FC, Zhang J*, Xia NS. Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial. Human Vaccines & Immunotherapeutics, 2014, 10(2): 1–7.(IF: 2.131)

[28] Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Yao X, Liang ZL, Wu T, Li JX, yan Q, Yang CL, Jiang HM, Huang HJ, Xian YL, Shih JW, Ng MH, Li YM, Wang JZ*, Zhu FC*, Xia NS*. Protection against hepatitis E virus infection by naturally acquired and vaccine induced immunity. Clin Microbiol Infect. 2014; 20: O397–O405(IF:4.54)

Invited Conference Oral Presentation:

[1] 12th Annual Meeting of Pakistan Society for the Study of Liver Disease (PSSLD), Karachi, Pakistan, 2018.12. Indication and Efficacy of HEV Vaccine.

[2] ISPE’s 11th Asian Conference on Pharmacoepidemiology, Xi’an, China, 2018.10. The post licensure clinical study of the recombinant hepatitis E vaccine.

[3] 15th International Symposium on Viral Hepatitis and Liver Disease, ISVHLD2015, Berlin, Germany, 2015.06. Vaccination Against Hepatitis E.

[4] Meeting on Appropriate Clinical Endpoints for 2nd Generation HPV Vaccine Trials, Geneva, Switzerland, 2014.11. The Progress in Development of Xiamen HPV Vaccine.

[5] Global advisory committee on vaccine safety, 2014.06. Development of Hecolin.

[6] Asian-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) 2014, Beijing China, 2014.04. Correlation between ELISA and Pseudovirion-based Neutralisation Assay for Detecting Antibodies against Human Papillomavirus Acquired by Natural Infection or by Vaccination.

[7] Meeting on Appropriate Clinical Endpoints for 2nd Generation HPV Vaccine Trials, Geneva, Switzerland, 2013.11. The Development of Xiamen HPV Vaccine.

[8] The DISCONTOOLS hepatitis E virus expert group meeting, Utrecht, Netherland, 2011.05. Development of a Hepatitis E Vaccine.

[9] MICROCON 2010, XXXIV National Conference of Indian Association of Medical Microbiologists, Kolkata, India, 2010.11. Hepatitis E- a Neglected Disease.

[10] 11th Annual General Meeting & Conference of DCVMN,  Hyderabad, India ,  2010.09.  Hepatitis E Vaccine (Hecolin)-Not a Moment Too Soon.


所获奖励:

[1] 求是杰出科技成就集体奖,香港求是科技基金会,国际学术奖,2015。(夏宁邵,李少伟,张军,吴婷,黄守杰,李益民,葛胜祥,顾颖,郑子峥,袁权,潘晖榕,吴文翰,赵勤俭,史维国,罗文新,陈毅歆,程通,俞海)


上一条:袁 权 下一条:苏迎盈

国家传染病诊断试剂与疫苗工程技术研究中心(厦门大学)  地址:中国福建省厦门市翔安区翔安南路厦门大学翔安校区
电话:0592-2183111 传真:0592-2181258  邮编:361102
ICP备案号:D200327